| Experiment ID | EXP00258 |
| Reference | Title: miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9. Author: Feliciano A, Castellvi J, Artero-Castro A, Leal JA, Romagosa C, Hernández-LosaJ, Peg V, Fabra A, Vidal F, Kondoh H, Ramón Y Cajal S, Lleonart ME. Journal: PLoS One. 2013 Oct 3;8(10):e76247. doi: 10.1371/journal.pone.0076247. eCollection2013. Abstract: MicroRNAs (miRNAs) play important roles in diverse biological processes and areemerging as key regulators of tumorigenesis and tumor progression. To explore thedysregulation of miRNAs in breast cancer, a genome-wide expression profiling of939 miRNAs was performed in 50 breast cancer patients. A total of 35 miRNAs were aberrantly expressed between breast cancer tissue and adjacent normal breasttissue and several novel miRNAs were identified as potential oncogenes or tumorsuppressor miRNAs in breast tumorigenesis. miR-125b exhibited the largestdecrease in expression. Enforced miR-125b expression in mammary cells decreasedcell proliferation by inducing G2/M cell cycle arrest and reducedanchorage-independent cell growth of cells of mammary origin. miR-125b was found to perform its tumor suppressor function via the direct targeting of the 3'-UTRs of ENPEP, CK2-α, CCNJ, and MEGF9 mRNAs. Silencing these miR-125b targets mimickedthe biological effects of miR-125b overexpression, confirming that they aremodulated by miR-125b. Analysis of ENPEP, CK2-α, CCNJ, and MEGF9 proteinexpression in breast cancer patients revealed that they were overexpressed in56%, 40-56%, 20%, and 32% of the tumors, respectively. The expression of ENPEPand CK2-α was inversely correlated with miR-125b expression in breast tumors,indicating the relevance of these potential oncogenic proteins in breast cancerpatients. Our results support a prognostic role for CK2-α, whose expression mayhelp clinicians predict breast tumor aggressiveness. In particular, our resultsshow that restoration of miR-125b expression or knockdown of ENPEP, CK2-α, CCNJ, or MEGF9 may provide novel approaches for the treatment of breast cancer. PMID: 24098452 |
| Expressiion Profile | Description: profile miRNA expression in breast cancer Organism: Homo sapiens GEO ID: GSE44124 Platform: GPL14767 Number of samples: 53 |
| Design and Sample | Cancer Type: breast cancer Cancer SubType: N/D Cell Line: N/D Experimental Design: cancer vs normal Case Sample: breast cancer Control Sample: normal breast Num of Case: 50 Num of Control: 3 Quantification Software: Limma Num of miRNAs: 851 |
| Identification | Num of Up: 8 Num of Down: 29 |